정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1710 | Completed | Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection | SARS-CoV Infection | Drug: Losartan | Phase 4 | Sharp HealthCare | OTHER | 31 | All | 18 Years | Sharp Grossmont Hospital, La Mesa, California, United States Sharp Chula Vista Medical Center, San Diego, California, United States Sharp Memorial Hospital, San Diego, California, United States |
| 1709 | Terminated | Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure | SARS-CoV-2 | Drug: Dociparstat sodium Drug: Placebo |
Phase 3 | Chimerix | INDUSTRY | 3 | All | 18 Years ~ 85 Years | University of Alabama at Birmingham, Birmingham, Alabama, United States Advanced Pulmonary Research Institute/Wellington Regional Medical Center, Loxahatchee Groves, Florida, United States Augusta University, Augusta, Georgia, United States Our Lady of the Lake, Baton Rouge, Louisiana, United States Tulane University, New Orleans, Louisiana, United States University Medical Center, New Orleans, Louisiana, United States William Beaumont Hospital, Royal Oak, Michigan, United States Wake Forest Baptist Health, Winston-Salem, North Carolina, United States Texas Health Harris Methodist Hospital Fort Worth, Dallas, Texas, United States Ascension St. Francis Hospital, Milwaukee, Wisconsin, United States Ascension All Saints Hospital, Racine, Wisconsin, United States |
| 1708 | Terminated | Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus? | SARS-CoV 2 | Drug: Hydroxychloroquine Drug: Placebo oral tablet |
Phase 3 | Megan Landes | OTHER | 13 | All | 18 Years | University Health Network, Toronto, Ontario, Canada |
| 1707 | Completed | Donated Antibodies Working Against nCoV | COVID-19 | Biological: Convalescent Plasma Drug: Standard of care |
Phase 2 | Universitaire Ziekenhuizen Leuven, Federal Knowledge Centre (KCE) | OTHER | 483 | All | 18 Years | ZNA, Antwerpen, Belgium Imelda Ziekenhuis Bonheiden, Bonheiden, Belgium Institut Bordet, Brussel, Belgium UMC Sint-Pieter, Brussel, Belgium CHU Brugmann, Brussel, Belgium Erasmus Ziekenhuis, Brussel, Belgium UZ Brussel, Brussel, Belgium Cliniques Universitaires St Luc, Brussel, Belgium AZ Sint-Vincentius, Deinze, Belgium AZ Maria Middelares, Gent, Belgium AZ Sint-Lucas, Gent, Belgium AZ Groeninge, Kortrijk, Belgium UZ Leuven, Leuven, Belgium CHC Liege Mont Legia, Liege, Belgium CHR Citadelle Liege, Liege, Belgium CHU Liege Sart-Tilman, Liege, Belgium CHU Ambroise Pare, Mons, Belgium CHR Jolimont Mons-Hainaut, Mons, Belgium AZ Delta, Roeselare, Belgium Sint-Trudo Ziekenhuis, Sint-Truiden, Belgium Centre Hospitalier de Wallonie Picarde (CHwapi), Tournai, Belgium |
| 1706 | Completed | Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) | ARDS | Drug: Dornase Alfa Inhalation Solution | Phase 3 | University of Missouri-Columbia | OTHER | 30 | All | 18 Years | University of Missouri Hospital and Clinics, Columbia, Missouri, United States |
| 1705 | Recruiting | Dornase Alpha for the Treatment of COVID-19 | COVID-19 | Drug: Pulmozyme | Phase 2 | Acibadem University, The Scientific and Technological Research Council of Turkey | OTHER | 60 | All | 18 Years | Acıbadem Altunizade Hospital, Istanbul, Turkey |
| 1704 | Active, not recruiting | Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects | SARS-CoV-2 Virus Infection | Biological: VLA2001 | Phase 2 | Valneva Austria GmbH, National Institute for Health Research, United Kingdom | INDUSTRY | 153 | All | 18 Years ~ 55 Years | Queen Elizabeth Hospital, Birmingham, United Kingdom University Hospital Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom Newcastle University Medical School, Newcastle, United Kingdom Southampton NIHR Clinical Research Facility, Southampton, United Kingdom |